These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10561241)

  • 21. BRCA1--lots of mutations, lots of dilemmas.
    Collins FS
    N Engl J Med; 1996 Jan; 334(3):186-8. PubMed ID: 8531977
    [No Abstract]   [Full Text] [Related]  

  • 22. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
    Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history.
    Beller U; Halle D; Catane R; Kaufman B; Hornreich G; Levy-Lahad E
    Gynecol Oncol; 1997 Nov; 67(2):123-6. PubMed ID: 9367693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
    Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
    Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1/2 germline mutations: a marker for radioresistance or radiosensitivity?
    Formenti SC; Preston-Martin S; Haffty BG
    J Clin Oncol; 2000 Mar; 18(5):1159-60. PubMed ID: 10694571
    [No Abstract]   [Full Text] [Related]  

  • 26. New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancer.
    Robson ME; Offit K
    Lancet; 1997 Jul; 350(9071):117-8. PubMed ID: 9228974
    [No Abstract]   [Full Text] [Related]  

  • 27. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
    Levy-Lahad E; Lahad A; King MC
    J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
    [No Abstract]   [Full Text] [Related]  

  • 28. Unknown significance.
    Couzin-Frankel J
    Science; 2014 Dec; 346(6214):1167-70. PubMed ID: 25477439
    [No Abstract]   [Full Text] [Related]  

  • 29. BRCA1 mutations in Ashkenazi Jewish women.
    Tonin P; Serova O; Lenoir G; Lynch H; Durocher F; Simard J; Morgan K; Narod S
    Am J Hum Genet; 1995 Jul; 57(1):189. PubMed ID: 7611288
    [No Abstract]   [Full Text] [Related]  

  • 30. The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer.
    Kreiss Y; Barak F; Baruch RG; Levy-Lahad E; Pras E; Friedman E
    Genet Test; 2000; 4(4):403-7. PubMed ID: 11216667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing for inherited susceptibility to breast cancer: a survey of informed consent forms for BRCA1 and BRCA2 mutation testing.
    Durfy SJ; Buchanan TE; Burke W
    Am J Med Genet; 1998 Jan; 75(1):82-7. PubMed ID: 9450863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The predictive value of BRCA1 and BRCA2 mutation testing.
    Bansal A; Critchfield GC; Frank TS; Reid JE; Thomas A; Deffenbaugh AM; Neuhausen SL
    Genet Test; 2000; 4(1):45-8. PubMed ID: 10794360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic predisposition testing: taking the lead.
    Muto MG
    Gynecol Oncol; 1997 Nov; 67(2):121-2. PubMed ID: 9367692
    [No Abstract]   [Full Text] [Related]  

  • 34. Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2.
    Foray N; Randrianarison V; Marot D; Perricaudet M; Lenoir G; Feunteun J
    Oncogene; 1999 Dec; 18(51):7334-42. PubMed ID: 10602489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A common BRCA1 mutation in the Ashkenazim.
    Goldgar DE; Reilly PR
    Nat Genet; 1995 Oct; 11(2):113-4. PubMed ID: 7550331
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
    Robson M; Dabney MK; Rosenthal G; Ludwig S; Seltzer MH; Gilewski T; Haas B; Osborne M; Norton L; Gilbert F; Offit K
    Genet Test; 1997; 1(1):47-51. PubMed ID: 10464625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The genetics of breast cancer: can we use today's information?
    Bell NN
    Manag Care Interface; 1998 May; 11(5):52-6. PubMed ID: 10181553
    [No Abstract]   [Full Text] [Related]  

  • 38. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
    Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
    Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
    Sarantaus L; Vahteristo P; Bloom E; Tamminen A; Unkila-Kallio L; Butzow R; Nevanlinna H
    Eur J Hum Genet; 2001 Jun; 9(6):424-30. PubMed ID: 11436123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Universal DNA array detection of small insertions and deletions in BRCA1 and BRCA2.
    Favis R; Day JP; Gerry NP; Phelan C; Narod S; Barany F
    Nat Biotechnol; 2000 May; 18(5):561-4. PubMed ID: 10802632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.